Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

718
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
718

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic and therapeutic applications of the glycan biomarker H3N2b in GM1 Gangliosidosis.

Molecular genetics and metabolism·2026
Same author

Pharmacotherapies for Gaucher disease: what's new on the horizon?

Expert opinion on pharmacotherapy·2026
Same author

New evidence on the clinical, genetic, and biochemical bases of GBA1-Parkinson's disease: prospects for treatment.

The Lancet. Neurology·2026
Same author

Commentary on Prenatal Testing of a Complex Pathogenic Variant following Positive Carrier Screening for Gaucher Disease.

Clinical chemistry·2025
Same author

The Race to Salvage Glucocerebrosidase: Understanding Small-Molecule Therapies for GBA1-Associated Parkinsonism.

Movement disorders : official journal of the Movement Disorder Society·2025
Same author

The Developmental Landscape of Children With Uveal Coloboma and Its Relationship With Clinical Phenotype and Genetics.

American journal of ophthalmology·2025

Related Experiment Video

Updated: Jan 4, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.0K

Variation in cognitive function over time in Gaucher disease type 3.

Alta M Steward1, Edythe Wiggs1, Taylor Lindstrom1

  • 1From the Section on Molecular Neurogenetics (A.M.S., E.W., T.L., S.U., E.R., N.T., T.R.L.G.L., E.S.), Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD; and Kimberly H. Courtwright and Joseph W. Summers Institute of Metabolic Disease (R.S.), Baylor Scott & White Research Institute, Dallas, TX. The present address for Tamanna Roshan Lal is Lysosomal Storage and Treatment Program, George Washington University School of Medicine and Children's National Rare Disease Institute, Washington DC.

Neurology
|November 14, 2019
PubMed
Summary
This summary is machine-generated.

Cognitive function in Gaucher disease type 3 patients varied individually over time, not showing linear decline. Establishing normal IQ variation is crucial for clinical trials of neurotherapeutics.

More Related Videos

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

12.7K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

27.8K

Related Experiment Videos

Last Updated: Jan 4, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.0K
Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
06:46

Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage

Published on: August 4, 2018

12.7K
Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

27.8K

Area of Science:

  • Neuroscience
  • Genetics
  • Clinical Trials

Background:

  • Gaucher disease type 3 is a rare genetic disorder affecting the brain.
  • Cognitive impairment is a significant challenge in Gaucher disease type 3.
  • Designing effective clinical trials for neurotherapeutics requires understanding cognitive variability.

Purpose of the Study:

  • To evaluate cognitive function longitudinally in patients with Gaucher disease type 3.
  • To identify relevant efficacy parameters for clinical trials of brain-penetrant therapies.
  • To characterize the variability of cognitive function over time in this patient population.

Main Methods:

  • Longitudinal cognitive assessment using Wechsler Intelligence Scales in 34 patients over 29 years.
  • Characterization of IQ variation using coefficient of variation (SD/mean).
  • Mixed-effects regressions to associate IQ with clinical features, controlling for potential confounders.

Main Results:

  • Mean verbal, performance, and full-scale IQs were 81.77, 75.98, and 82.02, respectively.
  • IQ variation was best characterized by coefficient of variation, showing no linear improvement or decline over time.
  • EEG lateralization and behavioral issues were significantly associated with IQ.

Conclusions:

  • Cognitive variability in Gaucher disease type 3 may be characteristic of other neuronopathic diseases.
  • Establishing a normal range of IQ variation is essential for using IQ as an efficacy measure in neurotherapeutic clinical trials.
  • Further research is needed to define clinically relevant IQ changes in Gaucher disease type 3.